Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  LJUBLJANA STOCK EXCHANGE, INC.  >  Krka d.d. Novo Mesto    KRKG   SI0031102120

KRKA D.D. NOVO MESTO (KRKG)
My previous session
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (EUR)
Sales 2018 1 311 M
EBIT 2018 200 M
Net income 2018 157 M
Finance 2018 53,5 M
Yield 2018 5,09%
Sales 2019 1 360 M
EBIT 2019 206 M
Net income 2019 162 M
Finance 2019 77,9 M
Yield 2019 5,34%
P/E ratio 2018 12,02
P/E ratio 2019 11,48
EV / Sales2018 1,41x
EV / Sales2019 1,34x
Capitalization 1 902 M
More Financials
Company
KRKA dd is a generic pharmaceutical company, which engages in the development, production, marketing, and sale of human and animal health products.It operates through the following geographical segments: European Union, South-East Europe, and Eastern Europe.The European Union segment includes all... 
Sector
Pharmaceuticals
Calendar
07/26 | 08:15amEarnings Release
More about the company
Surperformance© ratings of Krka d.d. Novo Mesto
Trading Rating : Investor Rating :
More Ratings
Latest news on KRKA D.D. NOVO MESTO
07/17KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
2017KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
2016KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
2015KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
2015KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
2014KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
2013KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
2012EU Sends Objections on Drug to Servier, Other Manufacturers
DJ
2012KRKA D.D. NOVO MESTO : Ex-dividend day for final dividend
FA
More news
Sector news : Generic Pharmaceuticals
03:02pBRISTOL MYERS SQUIBB : Myers Chief Commercial Officer Gordon Resigns
DJ
10:43aCHINA'S LATEST CONSUMER SCANDAL : Unsafe Vaccines
DJ
08:16aSHIRE PLC SHIRE PLC : Notice Of Results
DJ
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
RE
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 61,5 €
Spread / Average Target 6,1%
EPS Revisions
Managers
NameTitle
Jože Colaric President-Management Board & CEO
Jože Mermal Chairman-Supervisory Board
Brane Kastelec Finance Director
Vinko Zupancic Director-API Research & Development
Aleš Rotar Director-Pharmaceutical Research & Development
Sector and Competitors